Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
This study is a multi-center randomized, controlled, and blinded clinical trial study that
 will be performed in four medical-educational centers. In this study, the samples will be
 selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and
 will be randomly divided into two groups, including a control group and an intervention
 group. The study will be conducted in four medical centers. From each center, 56 definitive
 Corona patients will be selected, who will be randomly divided into two groups of 28, for a
 total of 224 patients will enter the study. In the intervention group, in addition to
 receiving the test spray, Patients will also receive standard treatment
Inclusion Criteria:

 -  Conscious consent to participate in the study

 -  Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR.

 -  Strong clinical suspicion of covid 19 with positive findings in CT Scan

 -  Shortness of breath

 Exclusion Criteria:

 -  Patients with HIV

 -  Patients with cancer undergoing chemotherapy

 -  Patients receiving Immune Mediators

 -  Patients need hospitalization in the intensive care unit

 -  Patients with uncontrolled heart, kidney or liver failure

 -  Pregnant or lactating women

 -  Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea,
 vomiting and respiratory problems)